tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

IKT Stock Latest News

Inhibikase Adjusts and Terminates Stock Offering Agreement
Company AnnouncementsInhibikase Adjusts and Terminates Stock Offering Agreement
2M ago
8K
IKT
Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders
PremiumThe Fly
Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders
2M ago
IKT
Inhibikase Therapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
Inhibikase Therapeutics Reports Q3 2024 Financial Results
3M ago
IKT
Inhibikase Therapeutics reports Q3 EPS (65c), consensus (48c)
PremiumThe Fly
Inhibikase Therapeutics reports Q3 EPS (65c), consensus (48c)
3M ago
IKT
Inhibikase Therapeutics, Inc. (IKT) Q3 Earnings Cheat Sheet
PremiumPre-Earnings
Inhibikase Therapeutics, Inc. (IKT) Q3 Earnings Cheat Sheet
3M ago
IKT
Molson Coors upgraded, Rivian downgraded: Wall Street’s top analyst calls
PremiumThe FlyMolson Coors upgraded, Rivian downgraded: Wall Street’s top analyst calls
3M ago
HD
SG
Inhibikase Therapeutics initiated with a Buy at Jefferies
Premium
The Fly
Inhibikase Therapeutics initiated with a Buy at Jefferies
3M ago
IKT
Inhibikase Therapeutics Secures Funding and Strengthens Leadership
Premium
Company Announcements
Inhibikase Therapeutics Secures Funding and Strengthens Leadership
3M ago
8K
IKT
Inhibikase Therapeutics closes up to $275M financing, advances IkT-001Pro
PremiumThe Fly
Inhibikase Therapeutics closes up to $275M financing, advances IkT-001Pro
3M ago
IKT
Inhibikase Therapeutics price target lowered to $5 from $15 at H.C. Wainwright
PremiumThe Fly
Inhibikase Therapeutics price target lowered to $5 from $15 at H.C. Wainwright
4M ago
IKT
Inhibikase Therapeutics Secures $110M for Drug Development
PremiumCompany Announcements
Inhibikase Therapeutics Secures $110M for Drug Development
4M ago
8K
IKT
Inhibikase Therapeutics prices 58.3M shares at $1.37 in private placement
PremiumThe Fly
Inhibikase Therapeutics prices 58.3M shares at $1.37 in private placement
4M ago
IKT
Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline
PremiumCompany AnnouncementsInhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline
4M ago
8K
IKT
Inhibikase Therapeutics reports Q2 EPS (66c), consensus (67c)
Premium
The Fly
Inhibikase Therapeutics reports Q2 EPS (66c), consensus (67c)
6M ago
IKT
IKT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
IKT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
6M ago
IKT
Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders
PremiumThe Fly
Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders
8M ago
IKT
Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders
PremiumThe Fly
Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders
8M ago
IKT
Inhibikase Therapeutics completes enrollment of Phase 2 ‘201’ trial
PremiumThe Fly
Inhibikase Therapeutics completes enrollment of Phase 2 ‘201’ trial
8M ago
IKT
Inhibikase Therapeutics announces expansion to its therapeutic pipeline
PremiumThe Fly
Inhibikase Therapeutics announces expansion to its therapeutic pipeline
8M ago
IKT
Inhibikase Therapeutics price target lowered to $23 from $27 at H.C. Wainwright
PremiumThe FlyInhibikase Therapeutics price target lowered to $23 from $27 at H.C. Wainwright
8M ago
IKT
Inhibikase announces pricing of registered direct offering, warrant inducement
Premium
The Fly
Inhibikase announces pricing of registered direct offering, warrant inducement
9M ago
IKT
Inhibikase Therapeutics reports Q1 EPS (73c) vs. (98c) last year
Premium
The Fly
Inhibikase Therapeutics reports Q1 EPS (73c) vs. (98c) last year
9M ago
IKT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >